

14th January, 2019

BSE Limited
P J Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 532300

National Stock Exchange of India Limited Exchange Plaza Bandra-Kurla Complex, Bandra (E), Mumbai 400 051

NSE Symbol - WOCKPHARMA

Dear Sirs,

Sub: Compliance Report on Corporate Governance

In compliance with Regulation 27(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Compliance Report on Corporate Governance for the quarter ended 31st December, 2018.

Kindly acknowledge receipt of the same.

Thanking you,

For Wockhardt Limited

Narendra Singh Company Secretary

Encl: As above

Ranked #1 in Healthcare

GREAT Best
Companies
to Work for 2015
India

	ter ending : 31st December, 2								
Com	position of Board of Direc	tors		/					
Title (Mr. / Ms)	Name of the Director	PAN & DIN		Category (Chairperson/Executive/ Non-Executive/Independent/ Nominee)	Date of Appointment in the current term	Tenure	No. of Directorship In listed entitles Including this listed entity (Refer Regulation 25(1) of Listing Regulations)	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No. of post of Chairperson in Audit's Stakeholder Committee held in listed entitles including this listed entity* (Refer Regulation 26(1) of Listing Regulatione)
Dr.	Habil F Khorakiwala	PAN	DIN	0.1	04.00.0045	92.92.929		,	
DI.	Habii F Kilorakiwala	AABPK4415C	00045608	Chairperson - Executive	01.03.2015	29.02.2020	1	U	
Dr.	Huzalfa H Khorakiwala	ABLPK6715C	02191870	Executive	31.03,2014	\$30,03,2019	1	1	
Dr,	Murtaza H Khorakiwala	AAZPK7040H	00102650	Managing Director - Executive	31.03.2014	\$ 30.03.2019	1	0	
Mr.	Shekhar Datta	AABPD6228L	00045591	Non-Executive - Independent	01.04.2014	31.03.2019	3	2	
Dr.	Sanjaya Baru	AAFPB4429H	05344208	Non-Executive - Independent	01.04.2014		2	3	
Mr.	Aman Mehta	AAGPM5030J	00009364	Non-Executive - Independent	01.04.2014	\$ 31.03.2019	6	6	
Mr.	D S Brar	AAGPB0665A	00068502	Non-Executive - Indépendent	01,04.2014		3	4	
Ms.	Tasneem Mehta	AAAPZ1346C	05009864	Non-Executive - Independent	30.09,2014	29.09.2019	1	2	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Mr.	Baldev Raj Arora	AAAPA5988R	00194168	Non-Executive - Independent	28.05.2015	27.05.2020	2	4	
Mr.	Vinesh Kumar Jairath	AAYPJ0756C	00391684	Non-Executive - Independent	10.11.2016	09.11.2021	5	7	
Ma.	Zehabiya H Khorakiwala	ANMPK3942N	00102689	Non-Executive - Non-Independent	30,10,2017		2	0	

Name of Committee		Name of Committee members	Category (Chairperson/Executive/Non-		
Name of Committee		Haune of Committee members	Executive/Independent/Nominee)		
I. Audit Committee		Mr. Shekhar Datta	Chairperson - Non-Executive - Independent		
		Mr. Aman Mehta	Non-Executive - Independent		
		Mr. D S Brar	Non-Executive - Independent		
		Dr. Sanjava Baru	Non-Executive - Independent		
		Ms. Taeneem Mohta	Non-Executive - Independent		
		Mr. Baldev Raj Arora	Non-Executive - Independent		
		Mr. Vinesh Kumar Jairath	Non-Executive - Independent		
2. Nomination & Remuneration Cor	nmittee	Mr. Shekhar Datta	Chairperson - Non-Executive - Independent		
		Dr. Habil F. Khorakiwala	Executive		
		Dr.Sanjaya Baru	Non-Executive - Independent		
		Mr. Aman Mehta	Non-Executive - Independent		
3. Risk Management Committee		N.A.	NA.		
4. Stakeholders Relationship Comr	nittee	Mr. Shekhar Datta	Chairperson - Non-Executive Independent		
		Mr. Aman Mehta	Non-Executive - Independent		
		Mr. D S Brar	Non-Executive - Independent		
		Dr. Sanjaya Baru	Non-Executive - Independent		
		Ms. Tasneem Mehta	Non-Executive - Independent		
		Mr. Baldev Raj Arora	Non-Executive - Independent		
		Mr. Vinesh Kumar Jairath	Non-Executive - Independent		
	4	Wit. Viresti Kullar Dalidui	Mon-executive - Independent		
III. Meeting of Board of Directors					
Date(s) of Meeting (if any) in the		Date(s) of Meeting (if any) in the relevant quarter	Maximum gap between any two consecutive (in number of days)		
	o providuo quartor	satisfer or mounty in any, in the research quarter	maximum gap sourcem any the consecutive (in number of days)		
04.08.2018		10.11.2018	97 (excluding date of meetings)		
			or texestating date of meetings)		
IV. Meeting of Committees**			or (excellent date of meanings)		
IV. Meeting of Committees** Date(s) of meeting of the	Whether requirement	Date(s) of meeting of the committee in the previous			
	Whether requirement				
Date(s) of meeting of the		Date(s) of meeting of the committee in the previous quarter			
Date(s) of meeting of the	of Quorum met				
Date(s) of meeting of the committee in the relevant quarter	of Quorum met (details)		Maximum gap between any two consecutive meetings in number of o		
Date(s) of meeting of the committee in the relevant quarter	of Quorum met (details)	quarter	Maximum gap between any two consecutive meetings in number of		
Date(s) of meeting of the committee in the relevant quarter 10.11.2018 ** Details provided only for Audit Con	of Quorum met (details)	quarter	Maximum gap between any two consecutive meetings in number of		
Date(s) of meeting of the committee in the relevant quarter 10.11.2018 Details provided only for Audit Conv. Related Party Transactions	of Quorum met (details)	quarter 04.08.2018	Maximum gap between any two consecutive meetings in number of 97 (excluding date of meetings)		
Date(s) of meeting of the committee in the relevant quarter 10.11.2018 ** Details provided only for Audit Con V. Related Party Transactions Subject	of Quorum met (details) Yes militee	quarter 04.08.2018	Maximum gap between any two consecutive meetings in number of 97 (excluding date of meetings)		
Date(s) of meeting of the committee in the relevant quarter 10.11.2018 ** Details provided only for Audit Con V. Related Party Transactions Subject	of Quorum met (details) Yes militee	quarter 04.08.2018	Maximum gap between any two consecutive meetings in number of 97 (excluding date of meetings)		
Date(s) of meeting of the committee in the relevant quarter 10.11.2018 ** Details provided only for Audit Con V. Related Party Transactions Subject Whether prior approval of audit co	of Quorum met (details) Yes militee	quarter 04.08.2018	Maximum gap between any two consecutive meetings in number of 97 (excluding date of meetings) lance status (Yes/No/NA) Yes		
Date(s) of meeting of the committee in the relevant quarter 10.11.2018 ** Details provided only for Audit Con V. Related Party Transactions Subject Whether prior approval of audit co	of Quorum met (details) Yes militee	quarter 04.08.2018	Meximum gap between any two consecutive meetings in number of 97 (excluding date of meetings)		
Date(s) of meeting of the committee in the relevant quarter 10.11.2018 Details provided only for Audit Conv. Related Party Transactions	of Quorum met (details) Yes militee minitee obtained	quarter 04.08.2018	Maximum gap between any two consecutive meetings in number of 97 (excluding date of meetings) lance status (Yes/No/NA) Yes		
Date(s) of meeting of the committee in the relevant quarter 10.11.2018 ** Details provided only for Audit Con V. Related Party Transactions Subject Whether prior approval of audit co	of Quorum met (details) Yes militiee mmilitiee obtained	quarter 04.08.2018	Meximum gap between any two consecutive meetings in number of 97 (excluding date of meetings) lance status (Yes/No/NA) Yes Yos		

@Transactions with Wockhardt Bio AG, Related Party, are considered material and approval of shareholders have been obtained at the Annual General Meeting held on 15th September, 2014. Further, pursuant to Regulation 27(2)(b) of SEBI (LODR) Regulations, 2015, the material transactions with Wockhardt Bio AG for the quarter ended 31st December, 2018 also forms part of this Report.

- VI. Affirmations

 1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Yes

 2. The composition of the following committees is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

 3. Audit Committee Yes

 b. Nomination & remuneration committee Yes
- b. Nomination & remuneration committee Yes
 c. Stakeholders relationship committee Yes
 d. Risk Management committee N.A.
 3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Yes
 4. The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Yes
 5. This report and/or the report submitted in the previous quarter has been placed before Board of Directors. Any comments/observations/advice of Board of Directors may be mentioned here:
 The Report for quarter ended 30th September, 2018 was placed before the Board of Directors at their meeting held on 10th November, 2018.
 This Report for the quarter ended 31st December, 2018 shall be placed before the Board at the ensuing Board Meeting.



14th January, 2019

WOCKHARDT LIMITED

DETAILS OF MATERIAL RELATED PARTY TRANSACTIONS FOR THE **QUARTER ENDED 31ST DECEMBER, 2018**

Name of Related Party	Name of transactions	Amount of transaction for the quarter ended 31st December, 2018 (Rs. in crores)
Wockhardt Bio AG	R&D Service	14.10
(Subsidiary Company)	Guarantee Fees Income	3.65
- 1	Management Fees	2.53
	Sales of Finished Goods	54.98
	Sale of Fixed Asset	1.04
	Expenses Recovered	0.20
4	Expenses Reimbursed	0.14
	Advances Received against Export of Goods & Services	46.91
	Advances Adjusted against Export of Goods & Services	51.44
	Total	174.99
Note: The	above figures are unaudited su	bject to review of Auditors

Narendra Singh

Company Secretary and Compliance Officer

14th January, 2019